AZD5492

AZD5492 is a T-cell engager developed by AstraZeneca. Its target is CD20 (the sponsor names CD20). The sponsor states: A CD8/TCR-based T-cell engaging antibody targeting CD20, administered subcutaneously to redirect T cells against CD20-positive B-cell malignancies. ClinicalTrials.gov describes the intervention as: CD8/TCR based T-cell engaging antibody targeting CD20, which is administered subcutaneously. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial. The largest, NCT06542250, plans to enrol 174 participants with primary completion expected 2029-12-18. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.